Zynerba Pharmaceuticals Inc

Most Recent

  • uploads///part
    Company & Industry Overviews

    Zynerba Pharmaceuticals: Analysts See More Upside after the Rally

    So far, Zynerba Pharmaceuticals (ZYNE) has seen an upwards price action of 265% in 2019. Analysts see more upside in the stock.

    By Mohit Oberoi, CFA
  • uploads///PE ratio
    Cannabis

    PE Ratio and the Basic Science of Stock Valuation

    Ratio analysis is a commonly used method of stock valuation. Among the most popular ratios, most investors tend to look at PE.

    By Mohit Oberoi, CFA
  • uploads///analysis _
    Company & Industry Overviews

    Zynerba Pharmaceuticals Rises Due to Patent News

    Zynerba Pharmaceuticals (ZYNE) has risen 18.6% as of 10:40 AM EST on June 11. The stock has year-to-date gains of more than 300%.

    By Mohit Oberoi, CFA
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.